Schizophrenia - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 309 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H1 2017, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 6
Schizophrenia - Overview 7
Schizophrenia - Therapeutics Development 8
Schizophrenia - Therapeutics Assessment 24
Schizophrenia - Companies Involved in Therapeutics Development 36
Schizophrenia - Drug Profiles 73
Schizophrenia - Dormant Projects 274
Schizophrenia - Discontinued Products 282
Schizophrenia - Product Development Milestones 285
Appendix 295

List of Tables

Number of Products under Development for Schizophrenia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Adamed Sp z oo, H1 2017
Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by AgeneBio Inc, H1 2017
Schizophrenia - Pipeline by Alkermes Plc, H1 2017
Schizophrenia - Pipeline by Angita BV, H1 2017
Schizophrenia - Pipeline by Astellas Pharma Inc, H1 2017
Schizophrenia - Pipeline by Athersys Inc, H1 2017
Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, H1 2017
Schizophrenia - Pipeline by BioCrea GmbH, H1 2017
Schizophrenia - Pipeline by BioHealthonomics Inc, H1 2017
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Schizophrenia - Pipeline by Braeburn Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H1 2017
Schizophrenia - Pipeline by Critical Pharmaceuticals Ltd, H1 2017
Schizophrenia - Pipeline by Curemark LLC, H1 2017
Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Schizophrenia - Pipeline by Delpor Inc, H1 2017
Schizophrenia - Pipeline by Denovo Biopharma LLC, H1 2017
Schizophrenia - Pipeline by Evotec AG, H1 2017
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Galenea Corp, H1 2017
Schizophrenia - Pipeline by GeNeuro SA, H1 2017
Schizophrenia - Pipeline by GlaxoSmithKline Plc, H1 2017
Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Schizophrenia - Pipeline by GP Pharm SA, H1 2017
Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H1 2017
Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2017
Schizophrenia - Pipeline by Heptares Therapeutics Ltd, H1 2017
Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
Schizophrenia - Pipeline by Indivior Plc, H1 2017
Schizophrenia - Pipeline by Insys Therapeutics Inc, H1 2017
Schizophrenia - Pipeline by IntelGenx Corp, H1 2017
Schizophrenia - Pipeline by Intra-Cellular Therapies Inc, H1 2017
Schizophrenia - Pipeline by Johnson & Johnson, H1 2017
Schizophrenia - Pipeline by JT Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by KemPharm Inc, H1 2017
Schizophrenia - Pipeline by Kowa Company Ltd, H1 2017
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2017
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2017
Schizophrenia - Pipeline by Lohocla Research Corp, H1 2017
Schizophrenia - Pipeline by Luye Pharma Group Ltd, H1 2017
Schizophrenia - Pipeline by Mapi Pharma Ltd, H1 2017
Schizophrenia - Pipeline by Merck & Co Inc, H1 2017
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Schizophrenia - Pipeline by Neurocrine Biosciences Inc, H1 2017
Schizophrenia - Pipeline by NeurOp Inc, H1 2017
Schizophrenia - Pipeline by Newron Pharmaceuticals SpA, H1 2017
Schizophrenia - Pipeline by Omeros Corp, H1 2017
Schizophrenia - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Schizophrenia - Pipeline by Peptron Inc, H1 2017
Schizophrenia - Pipeline by Pfizer Inc, H1 2017
Schizophrenia - Pipeline by Promentis Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Ra Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Richter Gedeon Nyrt, H1 2017
Schizophrenia - Pipeline by Sage Therapeutics Inc, H1 2017
Schizophrenia - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Suven Life Sciences Ltd, H1 2017
Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H1 2017
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc, H1 2017
Schizophrenia - Pipeline by Vitality Biopharma Inc, H1 2017
Schizophrenia - Pipeline by VLP Therapeutics LLC, H1 2017
Schizophrenia - Pipeline by Zogenix Inc, H1 2017
Schizophrenia - Pipeline by Zysis Ltd, H1 2017
Schizophrenia - Dormant Projects, H1 2017
Schizophrenia - Dormant Projects, H1 2017 (Contd..1), H1 2017
Schizophrenia - Dormant Projects, H1 2017 (Contd..2), H1 2017
Schizophrenia - Dormant Projects, H1 2017 (Contd..3), H1 2017
Schizophrenia - Dormant Projects, H1 2017 (Contd..4), H1 2017
Schizophrenia - Dormant Projects, H1 2017 (Contd..5), H1 2017
Schizophrenia - Dormant Projects, H1 2017 (Contd..6), H1 2017
Schizophrenia - Dormant Projects, H1 2017 (Contd..7), H1 2017
Schizophrenia - Discontinued Products, H1 2017
Schizophrenia - Discontinued Products, H1 2017 (Contd..1), H1 2017
Schizophrenia - Discontinued Products, H1 2017 (Contd..2), H1 2017